Saxol

Neuroprotecting

Patient's Future

Philippe Bordeau, CEO
February 2025

First Preventive Treatment for all Peripheral Neuropathies causes

'...the findings are truly impressive. I am convinced that Carba1 holds significant promise as an innovative solution'
Pr Ahmet Höke, PhD, MD, Johns Hopkins Medicine, Department of Neurology (MD)

Saxol at a glance

Saxol
Neuroprotecting
Patient's Future

- **A young pre-clinical stage biotech piloted by a skilled team**
  - Strong, visionary & complementary team (Science, CMC, Reg, ...)
  - Intl Scientific Medical Board Installed
- **Assets**
  - Pipeline patented, NAMPT activators, NAD^+
  - Free to Operate
- **Unmet Medical Need (no product preventing PN)**
  - CIPN, a major Unmet Medical Need as first indication
  - DPN, immunotherapy, Aging PN,... further indications
- **Strong body of evidence already available**
  - In vitro & in vivo strong efficacy proofs to support a Phase IB/IIA study
  - Ready to launch CMC & preclinical tox programs
- **Robust Roadmap incl. Health Agencies scientific advices**

CarbaS

Fast Track

Breakthrough therapeutics

Wide scope of indications

Fundraising

Raising € 2m capital

€ 5m equity to reach Clinic

€ 10+bn SAM
(on primary indication only)

Team

Saxol
Neuroprotecting
Patient's Future

Founders & Executive Team

Philippe Bordeau, MSc
Saxol CEO
Founder of several Biotechs
Strategy, IP, Collaborations, Financing skills including non dilutive multiple financing
20 M€ on 40 M€ for Alaxia

Victor Juarez Perez, PhD, MBA
Saxol CSO/COO
Team Leader of several pharma complex programs (ALX-009, STR-324…).
Scientific and regulatory strategy, interactions with FDA/EMA.
+20 articles in peer-review journals

Laurence Lafanechère, PhD,
Saxol Scientific adviser
IAB deputy director
Carba1 Inventor
Member of Ruban rose Scientific Committee , +80 publications

Lauriane Bosc, MSc
Saxol Preclinical Manager
Study engineer on several FUI projects
3y working on Saxol project

Paul Claudon, Ing, PhD
Saxol Head of CMC
Medicinal chemist managing drug manufacturing, analytics and quality aspects

Scientific & Medical advisory board

Ahmet Hoke, MD, PhD
Pr Neurology Johns Hopkins,
Head Neuromuscular Division
Editor in chief *Experimental Neurology*, Annals of Clinical and Translational Neurology
Author of 174 publications

Annie Claude Benichou, MD
Methodologist, Former QPPV and Medical Director of Stragen group
CMO of several drug dvpt program (OMA, STR-324,…)

Jesus Garcia-Foncillas Lopez MD PhD
Pr Oncology, Madrid University
Dr Cancer Institute
Dr Oncohealth Institute
Dr Department of Oncology at FJD Univ. Hosp.
Dr Translational Oncology Research Institute FJD
Author of 220 publications and several books on cancer

Context: Peripheral Neuropathy (PN)

Saxol
Neuroprotecting
Patient's Future

PN, a disorder affecting peripheral nerves
outside the brain and spinal cord

Nerve damage symptoms

- Sensitivity disorders
- Neuropathic Pain
- Muscles weakness
- Hearing loss
- Cognitive

PN Impact on daily life

- Loss of balance and increased risk of fall
- Motor impairment
- Reduced quality of life
- Depression, anxiety and insomnia



Problem: PN causes are not treated & multiple

Saxol
Neuroprotecting
Patient's Future

- Drug adverse side effects
  - Immunotherapies (Emerging adverse event)
  - Chemotherapies (Chemotherapy-Induced Peripheral Neuropathy - CIPN)
    - 10 Million/y patients treated worldwide (15 M in 2040)
- Neurodegenerative diseases
  - Alzheimer, Parkinson, etc. - over 70 Million patients (WHO)
- Metabolic
  - >530 Million diabetes patients in 2021 (> 700 Millions by 2040)
  - Gangrene & amputation risks
- Aging
  - 7-12% of general non-diabetic population
  - Over 750 Million people worldwide >65yo
- Trauma

Millions of patients with no therapeutic options

No preventing/curing treatment available for nerve fibers

One common cellular origin

Saxol
Neuroprotecting
Patient's Future

NAD^+

NERVE FIBERS DAMAGE

Chemo Induced PN

Diabetes PN

Aging

Other PN

Trauma



Our solution: Carba1

Saxol
Neuroprotecting
Patient's Future

Carba1 NAMPT activator restores NAD+ intracellular levels



Normal NAD+ salvage pathway



In neuropathic conditions **NAD+** production is **impaired**



Carba1 rescues NAD+ production by activation of NAMPT

NAD+, nucleotide present in all living cells.
NAD+, cofactor & substrate for a multitude of essential processes including energy production, DNA repair,...
NAMPT, key enzyme producing **NAD+**

Breakthrough therapeutic approach

Results: Strong evidence of effectiveness detailed in Annex

CarbaS : New class of Drugs

L. Lafanechère Team Invention, Grenoble

Saxol
Neuroprotecting
Patient's Future

- Carba1 - Lead and first product from our pipeline
- Breakthrough therapeutic approach
  - First in class
  - New MoA - NAMPT activator: NAD^+
  - Protecting nerve fibers
- Derived from a Carbazole structure
- Other derivatives available
- Pipeline Patented & Free to Operate



New class of drugs: NAMPT activators

Chemotherapy-Induced Peripheral Neuropathy

Saxol
Neuroprotecting
Patient's Future

- **A very common cancer treatment adverse event**
  - 70% of patients are affected after one month of treatment
  - 30% of patients remain affected 6 months after ending treatment
  - Usual cause of treatment interruption or dose reduction
  - No Clinical Study difficulty identified
- **Chemotherapy use in cancer treatment : > 50%***
  - 10 Million patients treated ww each year by chemo - 15 Million patients in 2040
  - € 10+bn SAM in EU - 3.1 Million CIPN patients EU+US

  *Even by 2040 – IARC/WHO – Wilson B, The Lancet
- **No treatment preventing CIPN nor PN approved**



Nerve ending degeneration due to lack of energy generated in mitochondria leads to chronic CIPN

FDA

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

Unmet Medical Need

Fast Track,
Breakthrough therapy,
PRIME

Competitive landscape for CIPN

Saxol
Neuroprotecting
Patient's Future

Opioids

....

> 60 Pain Killers

- ✘ Pain only – no interest shown by therapists
- ✘ Not addressing root cause
- ✘ Not preventing nor curing

Anti-epilectics

- ✘ CNS side-effect
- ✘ Risk of respiratory issues
- Poor efficacy

Anti-depressants

- ✘ Long timeframe for "efficacy"
- ✘ Cognitive impairment
- Poor efficacy

No nerve fibers protection

✓

Preventing Therapies
CIPN early-stage dvpt

Saxol
Neuroprotecting
Patient's Future

SONNET BioTherapeutics

AUGUSTINE therapeutics

OSMOL

Lilly

€ 17m - 06/24

Effectiveness - Strong evidence available

Saxol
Neuroprotecting
Patient's Future

Carba1 *In vitro* Neuroprotection





Carba1 *In vitro* effects on neuropathies induced by Cisplatin



Effectiveness

Strong evidence available

Carba1 In vivo *evidence on Neuroprotection*







Detailed Roadmap for CIPN

Saxol
Neuroprotecting
Patient's Future



timeline

CIPN PhaseIIB
Compassionate...

Diabetes
Aging
Trauma ...

Licensing out

CIPN
PhaseIB/IIA

Funding 3 – mid- 2028 — € 7 -m
Milestone 2 :
Subacute tox done,
IMPD & IB Draft

Funding 2 – Q1 2027 — € 3.0m
Milestone 1: CMC dossier
for DP/DS prod

Funding 1 – Q4 2025 — € 2.0m

Investment Thesis: 2m€

Saxol
Neuroprotecting
Patient's Future

- **Use of Funds**
  - Scientific development 65%
  - G&A 15%
  - Salaries 20%
- **Financing**
  - € 2m up to Milestone 1 (CMC dossier for DP/DS production)
  - Total Financing until Phase IIA
    - Equity € 5m
    - Non-dilutive funding € 1.9m
    - Debt € 0.1m
  - Further Equity round for Phase IIA: € 7m
  - Total Carba1 program (60mo) : Cost estimate € 17-20m (incl. 30% non-dilutive)
- **Exit**
  - Licensing out after Clinical Phase IIA

Capital Table - 02.2025



Saxol

Neuroprotecting Patient's Future

Follow us

www.saxol.eu

contact@saxol.eu

Supported by Linksium cnrs bpifrance